Peer-ReviewedPubMedResearch ArticleJAMA · 2026
Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer: Research Summary.
Identifiers
PubMed ID: 42593773
Radar topics
Related in the same topic
International journal of clinical oncology · 2026
Clinical indications and implications of metastasis-directed therapy and primary-site treatment in metastatic urothelial carcinoma.
Physical and engineering sciences in medicine · 2026
The use of Perspex-based devices in patient specific quality assurance of Acuros XB plans.
JAMA · 2026
Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer: A Randomized Clinical Trial.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique · 2026
Long-term control after stereotactic body radiotherapy for perineal recurrence of prostate cancer after radical prostatectomy and radiotherapy: A case report and review of the literature.
International journal of radiation oncology, biology, physics · 2026
Phase I/II Trial of Durvalumab plus Tremelimumab and Stereotactic Body Radiotherapy for Metastatic Head and Neck Carcinoma.
Practical radiation oncology · 2026
Impact of Volume and Image Strategy on Dose Prescription Accuracy in Lung Stereotactic Body Radiation Therapy.